30 September 2022 : Clinical Research
Effects of Left Atrial Appendage Closure on Neuroendocrine Function in Patients with Nonvalvular Atrial Fibrillation
Fei Wang1ABE*, Zhong-bao Ruan1BDG, Ge-cai Chen1BC, Jun-guo Zhu1CF, Li Zhu1ADOI: 10.12659/MSM.937586
Med Sci Monit 2022; 28:e937586
Table 1 Baseline characteristics of the included patients.
| Baseline characteristics (n=20) | |
|---|---|
| Age, years | 69.35±8.29 |
| Female, n (%) | 4 (20%) |
| Body mass index, kg/m | 24.78±3.14 |
| Coronary artery disease | 6 (30%) |
| Hypertension, n (%) | 11 (55%) |
| Diabetes mellitus, n (%) | 5 (25%) |
| Stroke/TIA/thromboembolism, n (%) | 7 (35%) |
| Vascular disease, n (%) | 12 (60%) |
| Congestive heart failure, n (%) | 5 (25%) |
| Abnormal liver function, n (%) | 1 (5%) |
| Abnormal renal function, n (%) | 3 (15%) |
| Labile INRs, n (%) | 6 (30%) |
| Alcohol, n (%) | 2 (10%) |
| CHADS-VASc | 3.00±1.45 |
| HAS-BLED | 2.52±0.89 |
| NVAF type | |
| Paroxysmal atrial fibrillation, n (%) | 3 (15%) |
| Persistent atrial fibrillation, n (%) | 17 (85%) |
| Left ventricular ejection fraction, % | 60.95±11.6 |
| Left atrial size, mm | 49.05±7.07 |
| Medicine drugs | |
| Angiotensin-converting enzyme inhibitors | 6 (30%) |
| Angiotonin receptor blockers | 7 (35%) |
| Aldosterone antagonists | 4 (20%) |
| Beta-blockers | 7 (35%) |